Lupus nephritis occurs in as many as half of patients presenting with systemic lupus erythematosus and is a major predictor of morbidity and mortality in this patient population. Prior to the last decade, the treatment of lupus nephritis was largely limited to corticosteroids, high-dose alkylating agents, and azathioprine, and this therapy was broadly prescribed regardless of patient demographics, clinical presentation, or prior toxicities.
INTRODUCTION
The presence of renal involvement adversely affects the outcome of patients with systemic lupus erythematosus (SLE). Severe renal disease is associated with increased mortality, progression to end-stage renal disease (ESRD), and a higher risk of treatment-related complications and toxicities. Through elegant but small randomized trials at the National Institutes of Health (NIH) in the 1970s and 1980s, monthly intravenous pulses of cyclophosphamide along with low-dose corticosteroids led to decreased long-term progression to renal failure compared with high-dose steroids alone, and thus became the standard lupus nephritis therapy. Despite this progress, resistance to therapy, relapses, and treatment-related toxicities remained common.
The last decade has seen further progress in the treatment of lupus nephritis. Mycophenolate mofetil (MMF) has emerged as an effective induction and maintenance therapy in severe lupus nephritis. Rituximab (RTX), already approved by the US Food and Drug Administration for rheumatoid arthritis, has been evaluated in large randomized controlled trials (RCTs). Calcineurin inhibitors (CNIs), used widely in solid-organ transplant patients, have been studied in small RCTs as induction, maintenance, and add-on therapy. Physicians now have many therapeutic options based increasingly on the data generated from RCTs. This review will discuss the key studies that have contributed to this amazing progress in the treatment of lupus nephritis over the last decade.
INDUCTION THERAPY
Initial treatment (induction therapy) uses higher doses of immunomodulatory agents in an attempt to quickly decrease the inflammation associated with a disease flare. cyclophosphamide (0.5-1 g/m 2 monthly for 6 months, followed by repeat dosing every 3 months) plus corticosteroids led to less long-term progression to renal failure than steroids alone in the treatment of lupus nephritis [1, 2] . This regimen was a major breakthrough in the treatment of lupus nephritis, but its associated adverse events were significant, particularly in a young SLE population at risk for gonadal toxicity and future malignancies.
In an attempt to decrease the adverse events, the 2002 Euro-Lupus Nephritis Trial (ELNT) randomized 90 lupus nephritis patients to low-dose intravenous cyclophosphamide (500 mg intravenous biweekly for 6 doses) vs. the high-dose NIH regimen [3] . All patients received steroids and azathioprine (AZA) maintenance therapy. The renal response and relapse rates were similar between the treatment groups (mean follow-up 41 months, 16% treatment failure in the low-dose group vs. 20% in the highdose group), and the long-term efficacy of this lowdose 'EUROLUPUS' regimen was confirmed in a subsequent 10-year follow-up study [4] . Although more infections were observed in the high-dose (mean cumulative dose 8.5 g) intravenous cyclophosphamide group vs. the low-dose (total dose 3 g) intravenous cyclophosphamide group, no statistically significant differences in the adverse events were observed.
Limitations of the ELNT study included the homogeneous Caucasian population, the fact that 78% of patients had preserved renal function (creatinine <1.3 mg/dl), the small number of patients treated, and that care was delivered at specialized referral centers. Regardless, low-dose intravenous cyclophosphamide was adopted in a variety of patient populations and clinical settings.
MMF is the most-studied alternative induction therapy to intravenous cyclophosphamide. After demonstrating efficacy and safety in renal transplant patients, MMF's potential as induction therapy for lupus nephritis was demonstrated in animal models [5, 6] and trials in patients with active lupus nephritis [7, 8] . The first RCT comparing MMF to cyclophosphamide randomized 42 patients to either 12 months of oral MMF (2 g/day for 6 months, then 1 g/day for 6 months) or 6 months of oral cyclophosphamide (2.5 mg/kg/day) followed by oral AZA (1.5 mg/kg/day) for 6 months. Both groups received corticosteroids. At 12 months, complete remission and partial remission rates, as well as relapse rates, were similar between the groups, but infections trended to be more common in the cyclophosphamide arm. At longer follow-up, the groups showed similar rates of chronic renal failure/ESRD and relapse. However, the higher frequency of infections was now significantly higher in the cyclophosphamide group, and deaths only occurred in the cyclophosphamide group.
Two large prospective RCTs have subsequently been performed. The first was a multicenter, open-label, noninferiority trial that randomized 140 patients with lupus nephritis to oral MMF (goal induction dose 3 g/day) plus steroids or high-dose intravenous cyclophosphamide plus steroids for 24 weeks [9] . Black (56%) and Hispanic (17%) patients, two demographic groups who have more resistant disease, were well represented. The primary endpoint was complete remission of renal disease, with partial remission as a secondary endpoint.
At 24 weeks, MMF therapy was associated with significantly improved complete remission (22.5%) and partial remission rates (29.6%) compared with intravenous cyclophosphamide (complete remission 5.8% and partial remission 24.6%), whereas relapse rates were similar on follow-up. Pyogenic infections were more common in the intravenous cyclophosphamide group, diarrhea was more common in the MMF group, and there was a nonsignificant trend toward lower mortality and renal failure in the MMF group. This study was limited in the cross-over design which may confound the intention-to-treat analysis and its restriction to patients from the United States. Nevertheless, this important trial demonstrated that MMF was a noninferior, and possibly even safer, induction therapy compared with intravenous cyclophosphamide.
The ALMS induction therapy trial followed, which randomized 370 patients with lupus nephritis treated with steroids in addition to either MMF or high-dose intravenous cyclophosphamide in a KEY POINTS Induction therapy with low-dose intravenous cyclophosphamide has similar efficacy as high-dose cyclophosphamide with lower cumulative drug exposure.
MMF is at least as effective as intravenous cyclophosphamide as induction therapy, and may have a better side-effect profile.
MMF and AZA have largely replaced cyclophosphamide as maintenance therapies.
Cyclosporine and tacrolimus have a role as both induction and maintenance therapies based on limited data.
Clinical experience suggests that RTX is a useful therapy in lupus nephritis, although the LUNAR trial did not demonstrate significantly improved renal outcomes in patients resistant to, or who relapsed after, firstline therapies.
diverse, multinational patient population [10] . With preset adjudicated endpoints, the cumulative remission rates were similar between the MMF (56%) and intravenous cyclophosphamide groups (53%), and all renal and nonrenal outcomes were equivalent at 6 months. These two RCTs solidified MMF as an induction therapy that was at least as effective, and possibly well tolerated, compared with intravenous cyclophosphamide. Recent analyses and smaller studies suggest that MMF is effective as induction therapy for both proliferative and membranous lupus nephritis [11] [12] [13] , crescentic lupus nephritis [14] , in black and Hispanic patients [15,16 & ] , and for extrarenal manifestations of SLE [17] .
Cyclosporine and tacrolimus
Three medium-sized RCTs have been conducted using cyclosporine as induction therapy in lupus nephritis. The first trial randomized 40 children with steroid-resistant proliferative lupus nephritis to receive cyclosporine (5 mg/kg/day) or oral cyclophosphamide (2 mg/kg/day) and prednisone (2 mg/kg/day). At 1 year, both groups achieved similar reductions in proteinuria [18] .
More than two decades later, a trial from the NIH randomized 42 patients with membranous lupus nephritis to three groups: cyclosporine plus prednisone for 11 months, alternate-month intravenous cyclophosphamide for 6 doses with prednisone, and alternate-day prednisone alone [19] . At 1 year, the cumulative remission rate was highest with cyclosporine (83%), intermediate with intravenous cyclophosphamide (60%), and lowest with prednisone (27%). While the cyclosporine group had the quickest remissions, there were fewer relapses with intravenous cyclophosphamide.
Most recently, 40 adults with newly diagnosed proliferative glomerulonephritis were randomized to induction therapy for 9 months with cyclosporine (4-5 mg/kg/day in divided doses) or intravenous cyclophosphamide (8 boluses of 10 mg/kg in 9 months), with steroids used in both groups [20] . More patients achieved complete remission of proteinuria in the cyclosporine group (69 vs. 38%, P ¼ 0.06), but a stable or improved creatinine occurred more often in the intravenous cyclophosphamide group compared with the cyclosporine group (86 vs. 47%).
Tacrolimus was initially found to have promise as induction therapy in lupus nephritis in openlabel pilot studies mostly in Chinese and Japanese patients [21] [22] [23] [24] . One RCT randomized eighty-one Chinese patients to tacrolimus plus steroids or highdose intravenous cyclophosphamide plus steroids and found similar rates of complete remission (52% tacrolimus vs. 39% intravenous cyclophosphamide) and cumulative remission (90% tacrolimus vs. 82% intravenous cyclophosphamide) at 6 months, with no difference in adverse events [25 & ]. A second trial randomized 60 patients with lupus nephritis to steroids plus either tacrolimus, MMF, or high-dose intravenous cyclophosphamide, and found similar complete remission rates (40% for MMF, 45% for tacrolimus, and 30% for cyclophosphamide) and cumulative remission rates (70, 75, and 60%, respectively) at 24 weeks [26] . Nonsignificant increases in infections with cyclophosphamide and MMF groups, irregular menstruation with cyclophosphamide, and hyperglycemia with tacrolimus were observed. Both trials demonstrated more rapid improvement in serum albumin and proteinuria with tacrolimus therapy.
A recent meta-analysis of RCTs comparing tacrolimus to intravenous cyclophosphamide analyzed these two trials and three others available only in Chinese, and concluded that tacrolimus was more effective and well tolerated than intravenous cyclophosphamide as induction therapy in Chinese patients [27] .
Although these trials indicate that CNIs may be well tolerated and effective in lupus nephritis, the lack of data on its efficacy in larger and more diverse cohorts prevents the designation of CNIs as first-line induction therapy. However, data showing improved outcomes with CNIs combined with MMF in 'multitarget' therapy highlights their value, particularly in difficult-to-treat patients [28] [29] [30] .
Rituximab
Research has implicated the importance of Blymphocytes in the pathogenesis SLE, making the direct targeting of B-cells an attractive therapeutic option for lupus nephritis [31] . The off-label use of RTX, a chimeric anti-CD20 monoclonal antibody, has now been extensively described in lupus nephritis. Small pilot and observational studies demonstrated that the addition of RTX to corticosteroids is as effective as RTX plus intravenous cyclophosphamide plus steroids in refractory lupus nephritis [32] , or oral cyclophosphamide plus steroids in relapsing lupus nephritis [33] . The Lupus Nephritis Assessment with Rituximab (LUNAR) trial is the largest study using RTX in lupus nephritis and randomized 144 patients with lupus nephritis to MMF and steroids plus add-on intravenous RTX therapy (1 g on day 1, 15, 168, and 182) or intravenous placebo given at similar intervals [34 && ]. Although there was a trend toward improvement in the primary endpoint (renal response) in the RTX group, this result did not reach significance (overall response 57 vs. 46%). RTX was associated with more neutropenia, leucopenia, and hypotension than the placebo group, but was otherwise well tolerated.
The results of the LUNAR trial and the EXPLORER trial [35] , which showed no difference in disease severity with RTX compared to placebo in SLE patients without lupus nephritis, were disappointing. However, the extensive experience with RTX as add-on therapy in lupus nephritis as well as the trend toward overall response in the RTX arm of the LUNAR trial prompts many physicians to consider RTX as a useful therapy in lupus nephritis. One review analyzed 26 reports comprising 300 patients with lupus nephritis treated with RTX with a mean follow-up of 60 weeks [36 & ] and found total (complete remission plus partial remission) remission rates achieved were 87, 76, and 67% in class III, IV, and V lupus nephritis, respectively. Further trials using RTX as add-on and initial therapy, as well as the identification of clinical or histologic predictors of RTX efficacy, are needed.
MAINTENANCE THERAPY
Prior to the last decade, maintenance therapy mostly consisted of a combination of intermittent intravenous cyclophosphamide and glucocorticoids (both associated with significant toxicity when used as chronic therapies) or AZA. As with induction therapy, the largest studies have established MMF as a first-line maintenance therapy in lupus nephritis. The first RCT evaluated 59 patients (including many blacks and Hispanics) who underwent induction therapy with high-dose intravenous cyclophosphamide plus steroids, then received maintenance therapy with MMF, AZA, or quarterly intravenous cyclophosphamide (all in combination with steroids) [37] . The primary endpoint was patient death and chronic renal failure. MMF and AZA both were superior to intravenous cyclophosphamide in this regard, and MMF was associated with the lowest relapse rate. Both oral agents had lower incidences of adverse events (hospitalization days, primary amenorrhea and infections) than intravenous cyclophosphamide. This prompted many physicians to abandon long-term intravenous cyclophosphamide in favor of well tolerated and more effective oral therapies.
Maintenance MMF and AZA in lupus nephritis have been compared in two large RCTs. The MAINTAIN Nephritis Trial [38] found no difference in renal flares over a 4-year follow-up period in European patients treated with MMF (19%) or AZA (25%), after induction with ELNT protocol intravenous cyclophosphamide and steroids in both groups. Cytopenias were more common in the AZA group. The ALMS maintenance trial randomized 227 patients who had achieved initial renal response during the induction trial (see above) to receive MMF or AZA [39 && ]. Over a 3-year follow-up period, the MMF group had less treatment failures (renal failure, death, and doubling of serum creatinine) and demonstrated a longer time-to-renal-flare and time-to-rescue-therapy. These results favored MMF regardless of induction therapy, patient demographics, or geography. The rates of serious adverse events were similar between the two groups, but more patients in the AZA arm withdrew because of adverse events. These studies have resulted in MMF or AZA being the recommended first-line maintenance therapies in lupus nephritis [40] [41] [42] .
Cyclosporine has been explored in two RCTs as maintenance therapy. The first trial compared cyclosporine plus steroids to AZA plus steroids after 3 months of induction therapy with oral cyclophosphamide and steroids [43] . The SLE relapse rates were the same in both groups, there was no difference in renal function, and more patients in the cyclosporine group achieved continued undetectable proteinuria at 4 years of follow-up. The second study prescribed 9 months of induction therapy with cyclosporine or intravenous cyclophosphamide (see above), then maintenance therapy with cyclosporine or oral cyclophosphamide [20] . At 9 months of maintenance therapy (18 months total therapy), remission rates were similar, but more patients in the cyclosporine group had complete remission in proteinuria.
Tacrolimus has been studied as maintenance therapy in one pilot study in Japanese patients [44] and one recent RCT in Chinese patients [45] . The RCT was an extension of the tacrolimus induction therapy RCT described above [25 & ] and randomized patients who achieved complete or partial remission to maintenance therapy with low-dose steroids plus either tacrolimus or AZA. At 6 months, relapses occurred in 0 of 33 patients in the tacrolimus group and 2 of 30 (7%) patients in the AZA group, and leucopenia was more common in the AZA group.
Familiarity with the long-term use of the CNIs in transplant patients makes their use as maintenance therapy in lupus nephritis an attractive option. However, the limited data and concern for nephrotoxicity with prolonged use prevent their designation as the first-line maintenance therapies in lupus nephritis.
ADJUNCTIVE THERAPY
Two commonly used adjunctive treatments in lupus nephritis are antimalarial agents and inhibitors of the renin-angiotensin-aldosterone system.
Antimalarial agents
The antimalarial agent hydroxychloroquine (HCQ) is commonly used in SLE and has multiple immunomodulatory effects. The Canadian Hydroxychloroquine Study Group demonstrated via a small randomized withdrawal trial that stable SLE patients who continued HCQ experienced less disease flares over a 24-week period compared with those who took placebo [46] . At 3 years of follow-up, there was a nonsignificant trend toward less renal flares (relative risk 0.26, 95% confidence interval 0.03-2.54, P ¼ 0.25) with continuing HCQ [47] . Subsequently, multiple cohort studies have been published following between 29 and 1480 patients with SLE and demonstrated that HCQ use was associated with significantly lower incidence and prevalence of renal disease [48, 49] and improved renal outcomes in lupus nephritis [50] [51] [52] [53] . HCQ may accumulate and cause retinopathy in up to 6% of patients, so regular ophthalmologic examinations are recommended. Given the extensive experience demonstrating the renal and extrarenal benefits of HCQ use, it should be considered in patients with lupus nephritis unless a contraindication exists.
Renin-angiotensin-aldosterone system blockade
Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) have become the standard-of-care therapies in proteinuric kidney diseases. The Lupus in Minorities: Nature vs. Nurture study demonstrated an association between ACEI use and less development of lupus nephritis in those who did not have renal disease, and an improvement in proteinuria and decreased risk of disease activity in those with established lupus nephritis [54] . Retrospective and prospective studies have shown improvements in proteinuria with ACEIs and ARBs in lupus nephritis [55] [56] [57] . This effect seems to be independent of the blood pressure control and, along with the other preclinical and human studies, implicates immunomodulatory effects of these medications. Therefore, ACEIs or ARBs should be used in all patients with lupus nephritis unless a contraindication exists.
SPECIAL CLINICAL CONSIDERATIONS
Women with SLE are 5-8 times more likely to have coronary heart disease than those in the general population [58, 59] . Although optimum cholesterol levels in lupus nephritis patients have not been established, it is appropriate to use statins in lupus nephritis similarly to other causes of chronic kidney disease. Osteopenia and osteoporosis are common in SLE, perhaps linked to excess glucocorticoid use, and lead to a five-fold increased risk of symptomatic fracture in SLE patients compared with the general population [60] . Management of bone disease with calcium and vitamin D supplementation should be considered in all patients with lupus nephritis. Finally, approximately 30% of patients with SLE will also develop the antiphospholipid antibody syndrome (APLS) and are at risk for thromboembolic events, renal thrombotic microangiography, and catastrophic APLS.
CONCLUSION
Extensive observational and randomized controlled trials during the last decade have demonstrated the effectiveness of multiple therapies in the induction and maintenance treatment of lupus nephritis. Lowdose intravenous cyclophosphamide and MMF have joined high-dose intravenous cyclophosphamide as the first-line induction regimens, and MMF or AZA have largely replaced cyclophosphamide as the first-line maintenance therapies. CNIs and RTX clearly have important roles in the treatment of lupus nephritis, but these roles are less well defined. Further clinical trials are necessary to pursue improved outcomes with less adverse events in the treatment of lupus nephritis.
